Inflammation markers in essential hypertension

Medicinal Chemistry

Volumn 10, Issue 7, 2014, Pages 672-681

  Tsounis, Dimitrios ^a   Bouras, Georgios ^a   Giannopoulos, Georgios ^b   Papadimitriou, Charalampos ^c   Alexopoulos, Dimitrios ^d   Deftereos, Spyridon ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hellenic Center for Disease Control and Prevention   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Adhesion molecules; Biomarkers; CRP; Cytokines; Hypertension; Inflammation; Target organ damage; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BISOPROLOL; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; METOPROLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; BIOLOGICAL MARKER;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); ESSENTIAL HYPERTENSION; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; ANIMAL; COMPLICATION; HYPERTENSION; IMMUNOLOGY; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; INFLAMMATION;

EID: 84925620421     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666140318111328     Document Type: Article

References (136)

1. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, D. E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S. E.; Laurent, S.; Manolis, A. J.; Nilsson, P. M.; Ruilope, L. M.; Schmieder, R. E.; Sirnes, P. A.; Sleight, P.; Viigimaa, M.; Waeber, B.; Zannad, F.; Redon, J.; Dominiczak, A.; Narkiewicz, K.; Nilsson, P. M.; Burnier, M.; Viigimaa, M.; Ambrosioni, E.; Caufield, M.; Coca, A.; Olsen, M. H.; Schmieder, R. E.; Tsioufis, C.; Van De Borne, P.; Zamorano, J. L.; Achenbach, S.; Baumgartner, H.; Bax, J. J.; Bueno, H.; Dean, V.; Deaton, C.; Erol, C.; Fagard, R.; Ferrari, R.; Hasdai, D.; Hoes, A. W.; Kirchhof, P.; Knuuti, J.; Kolh, P.; Lancellotti, P.; Linhart, A.; Nihoyannopoulos, P.; Piepoli, M. F.; Ponikowski, P.; Sirnes, P. A.; Tamargo, J. L.; Tendera, M.; Torbicki, A.; Wijns, W.; Windecker, S.; Clement, D. L.; Coca, A.; Gillebert, T. C.; Tendera, M.; Rosei, E. A.; Ambrosioni, E.; Anker, S. D.; Bauersachs, J.; Hitij, J. B.; Caulfield, M.; De Buyzere, M.; De Geest, S.; Derumeaux, G. A.; Erdine, S.; Farsang, C.; Funck-Brentano, C.; Gerc, V.; Germano, G.; Gielen, S.; Haller, H.; Hoes, A. W.; Jordan, J.; Kahan, T.; Komajda, M.; Lovic, D.; Mahrholdt, H.; Olsen, M. H.; Ostergren, J.; Parati, G.; Perk, J.; Polonia, J.; Popescu, B. A.; Reiner, Z.; Rydén, L.; Sirenko, Y.; Stanton, A.; Struijker-Boudier, H.; Tsioufis, C.; Van De Borne, P.; Vlachopoulos, C.; Volpe, M.; Wood, D. A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart. J. 2013, 34(28), 2159-219.
2. Colosia, A. D.; Palencia, R.; Khan, S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr. Obes. 2013, 6, 327-338.
3. Elliott, W. J. The economic impact of hypertension. J. Clin. Hypertens. (Greenwich) 2003, 5(3 Suppl 2), 3-13.
4. Millar, J. A.; Waal-Manning, H. J. Current treatment of hypertension. Part 2: Risk factors, drug treatment and economic aspects. N. Z. Med. J. 1992, 105(928), 61-3.
5. Hall, J. E.; Granger, J. P.; Do Carmo, J. M.; Da Silva, A. A.; Dubinion, J.; George, E.; Hamza, S.; Speed, J.; Hall, M. E. Hypertension: physiology and pathophysiology. Compr. Physiol. 2012, 2(4), 2393-442.
6. Androulakis, E. S.; Tousoulis, D.; Papageorgiou, N.; Tsioufis, C; Kallikazaros, I.; Stefanadis, C. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol. Rev. 2009, 17(5), 216-21.
7. Quiroz, Y.; Johnson, R. J.; Rodríguez-Iturbe, B. The role of T cells in the pathogenesis of primary hypertension. Nephrol. Dial. Transplant. 2012, 27(Suppl 4), iv2-5.
8. Schiffrin, E. L. The immune system: role in hypertension. Can. J. Cardiol. 2013, 29(5), 543-8.
9. Schiffrin, E. L. Immune mechanisms in hypertension and vascular injury. Clin. Sci. (Lond.) 2014, 126(4), 267-74.
10. Crowley, S. D. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid. Redox. Signal. 2014, 20(1), 102-20.
11. Savoia, C; Schiffrin, E. L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 2006, 15(2), 152-8.
12. Li, J.-J.; Chen, J.-L. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med. Hypotheses. 2005, 64(5), 925-9.
13. Harrison, D. G.; Marvar, P. J.; Titze, J. M. Vascular inflammatory cells in hypertension. Front. Physiol. 2012, 3, 128.
14. Saleh, M. A.; Pollock, D. M. Endothelin in renal inflammation and hypertension. Contrib. Nephrol. 2011, 172, 160-70.
15. Briones, A. M.; Touyz, R. M. Oxidative stress and hypertension: current concepts. Curr. Hypertens. Rep. 2010, 12(2), 135-42.
16. Ryan, M. J. An update on immune system activation in the pathogenesis of hypertension. Hypertension 2013, 62(2), 226-30.
17. Ghanem, F. A.; Movahed, A. Inflammation in high blood pressure: a clinician perspective. J. Am. Soc. Hypertens. 2007, 1(2), 113-9.
18. Stefanadi, E.; Tousoulis, D.; Androulakis, E. S.; Papageorgiou, N.; Charakida, M.; Siasos, G.; Tsioufis, C; Stefanadis, C. Inflammatory markers in essential hypertension: potential clinical implications. Curr. Vasc. Pharmacol. 2010, 8(4), 509-16.
19. Pepys, M. B.; Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111(12), 1805-12.
20. Schillaci, G.; Pirro, M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr. Metab. Cardiovasc. Dis. 2006, 16(7), 500-8.
21. Hage, F. G. C-reactive protein and hypertension. J. Hum. Hypertens. 2013, [Epub ahead of print].
22. Kaptoge, S.; Di Angelantonio, E.; Lowe, G.; Pepys, M. B.; Thompson, S. G.; Collins, R.; Danesh, J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709), 132-40.
23. Bautista, L. E.; López-Jaramillo, P.; Vera, L. M.; Casas, J. P.; Otero, A. P.; Guaracao, A. I. Is C-reactive protein an independent risk factor for essential hypertension? J. Hypertens. 2001, 19(5), 857-61.
24. Kong, H.; Qian, Y.-S.; Tang, X.-F.; Zhang, J.; Gao, P.-J.; Zhang, Y.; Zhu, D.-L. C-reactive protein (CRP) gene polymorphisms, CRP levels and risk of incident essential hypertension: findings from an observational cohort of Han Chinese. Hypertens. Res. 2012, 35(10), 1019-23.
25. Kozan, O.; Buyukozturk, K.; Ilerigelen, B.; Kabakci, G.; Koylan, N.; ICEBERG Investigators, The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients: results of the ICEBERG study. J. Clin. Hypertens. (Greenwich) 2007, 9(7), 500-5.
26. Kuklinska, A. M.; Mroczko, B.; Musial, W. J.; Sawicki, R.; Kozieradzka, A.; Waszkiewicz, E.; Szmitkowski, M. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia. Adv. Med. Sci. 2009, 54(2), 225-32.
27. Sung, K. C; Suh, J. Y.; Kim, B. S.; Kang, J. H.; Kim, H.; Lee, M. H.; Park, J. R.; Kim, S. W. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am. J. Hypertens. 2003, 16(6), 429-33.
28. Sesso, H. D.; Buring, J. E.; Rifai, N.; Blake, G. J.; Gaziano, J. M.; Ridker, P. M. C-Reactive Protein and the Risk of Developing Hypertension. JAMA 2003, 290(22), 2945-2951.
29. Torun, D.; Ozelsancak, R.; Yigit, F.; Micozkadioglu, H. Increased inflammatory markers are associated with obesity and not with target organ damage in newly diagnosed untreated essential hypertensive patients. Clin. Exp. Hypertens. 2012, 34(3), 171-5.
30. Wang, T. J.; Gona, P.; Larson, M. G.; Levy, D.; Benjamin, E. J.; Tofler, G. H.; Jacques, P. F.; Meigs, J. B.; Rifai, N.; Selhub, J.; Robins, S. J.; Newton-Cheh, C; Vasan, R. S. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007, 49(3), 432-8.
31. Ozcan, F.; Turak, O.; Durak, A.; Işleyen, A.; Uçar, F.; Giniş, Z.; Uçar, F.; Başar, F. N.; Aydogdu, S. Red cell distribution width and inflammation in patients with non-dipper hypertension. Blood Press. 2013, 22(2), 80-5.
32. Turak, O.; Ozcan, F.; Tok, D.; Işleyen, A.; Sökmen, E.; Taşoglu, I.; Aydogdu, S.; Sen, N.; McFann, K.; Johnson, R. J.; Kanbay, M. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J. Clin. Hypertens. (Greenwich) 2013, 15(1), 7-13.
33. Sathiyapriya, V.; Selvaraj, N.; Nandeesha, H.; Bobby, Z.; Aparna, A.; Pavithran, P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin. Exp. Hypertens. 2008, 30(5), 367-74.
34. Navarro-González, J. F.; Mora, C; Muros, M.; García, J.; Donate, J.; Cazaña, V. Relationship between inflammation and microalbuminuria in prehypertension. J. Hum. Hypertens. 2013, 27(2), 119-25.
35. Díaz, J. J.; Arguelles, J.; Málaga, I.; Perillán, C; Diéguez, A.; Vijande, M.; Málaga, S. C-reactive protein is elevated in the offspring of parents with essential hypertension. Arch. Dis. Child. 2007, 92(4), 304-8.
36. Lande, M. B.; Pearson, T. A.; Vermilion, R. P.; Auinger, P.; Fernandez, I. D. Elevated blood pressure, race/ethnicity and C-reactive protein levels in children and adolescents. Pediatrics 2008, 122(6), 1252-7.
37. Litwin, M.; Michalkiewicz, J.; Niemirska, A.; Gackowska, L.; Kubiszewska, I.; Wierzbicka, A.; Wawer, Z. T.; Janas, R. Inflammatory activation in children with primary hypertension. Pediatr. Nephrol. 2010, 25(9), 1711-8.
38. Tsioufis, C; Syrseloudis, D.; Dimitriadis, K.; Thomopoulos, C; Tsiachris, D.; Pavlidis, P.; Selima, M.; Kallikazaros, I.; Stefanadis, C. Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J. Hum. Hypertens. 2008, 22(7), 501-8.
39. Kim, K.-I.; Lee, J.-H.; Chang, H.-J.; Cho, Y.-S.; Youn, T.-J.; Chung, W.-Y.; Chae, I.-H.; Choi, D.-J.; Park, K. U.; Kim, C.-H. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ. J. 2008, 72(2), 293-8.
40. Pedrinelli, R.; Dell'Omo, G.; Di Bello, V.; Pellegrini, G.; Pucci, L.; Del Prato, S.; Penno, G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler. Thromb. Vasc. Biol. 2004, 24(12), 2414-9.
41. Tsioufis, C; Dimitriadis, K.; Taxiarchou, E.; Vasiliadou, C; Chartzoulakis, G.; Tousoulis, D.; Manolis, A.; Stefanadis, C; Kallikazaros, I. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am. J. Hypertens. 2006, 19(5), 462-6.
42. Perticone, F.; Maio, R.; Tripepi, G.; Sciacqua, A.; Mallamaci, F.; Zoccali, C. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J. Nephrol. 2007, 20(Suppl 12), S56-62.
43. Ferroni, P.; Guagnano, M. T.; Falco, A.; Paoletti, V.; Manigrasso, M. R.; Michetti, N.; Santilli, F.; Guadagni, F.; Basili, S.; Davì, G. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin. Sci. (Lond.) 2008, 114(6), 449-55.
44. Assadi, F. Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr. Cardiol. 2008, 29(3), 580-4.
45. Tsioufis, C; Dimitriadis, K.; Andrikou, E.; Thomopoulos, C; Tsiachris, D.; Stefanadi, E.; Mihas, C; Miliou, A.; Papademetriou, V.; Stefanadis, C. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am. J. Kidney. Dis. 2010, 55(6), 1050-9.
46. Gupta, V.; Sachdeva, S.; Khan, A. S.; Haque, S. F. Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi. J. Kidney. Dis. Transpl. 2011, 22(1), 97-103.
47. Berni, A.; Ciani, E.; Bernetti, M.; Cecioni, I.; Berardino, S.; Poggesi, L.; Abbate, R.; Boddi, M. Renal resistive index and low-grade inflammation in patients with essential hypertension. J. Hum. Hypertens. 2012, 26(12), 723-30.
48. Moura, R.d. S. S. E. S.; Vasconcelos, D. F.; Freitas, E.; Moura, F. J. D.d.; Rosa, T. T.; Veiga, J. P. R.; Cystatin, C. CRP, log TG/HDLc and metabolic syndrome are associated with microalbuminuria in hypertension. Arq. Bras. Cardiol. 2014, 102(1), 54-9.
49. Assadi, F. C-reactive protein and incident left ventricular hypertrophy in essential hypertension. Pediatr. Cardiol. 2007, 28(4), 280-5.
50. Tsai, W.-C; Lin, C.-C; Huang, Y.-Y.; Chen, J.-Y.; Chen, J.-H. Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non-diabetic hypertensive patients. Blood Press. 2007, 16(4), 270-5.
51. Turak, O.; Özcan, F.; Canpolat, U.; Işleyen, A.; Cebeci, M.; Öksüz, F.; Mendi, M. A.; Çagli, K.; Gölbaşi, Z.; Aydogdu, S. Increased echocardiographic epicardial fat thickness and high-sensitivity CRP level indicate diastolic dysfunction in patients with newly diagnosed essential hypertension. Blood Press. Monit. 2013, 18(5), 259-64.
52. Kampus, P.; Muda, P.; Kals, J.; Ristimäe, T.; Fischer, K.; Teesalu, R.; Zilmer, M. The relationship between inflammation and arterial stiffness in patients with essential hypertension. Int. J. Cardiol. 2006, 112(1), 46-51.
53. Pietri, P.; Vyssoulis, G.; Vlachopoulos, C; Zervoudaki, A.; Gialernios, T.; Aznaouridis, K.; Stefanadis, C. Relationship between lowgrade inflammation and arterial stiffness in patients with essential hypertension. J. Hypertens. 2006, 24(11), 2231-8.
54. Jastrzebski, M.; Czarnecka, D.; Rajzer, M.; Kawecka-Jaszcz, K. Increased levels of inflammatory markers in hypertensives with target organ damage. Kardiol. Pol. 2006, 64(8), 802-9; discussion 810-1.
55. Mahmud, A.; Feely, J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005, 46(5), 1118-22.
56. Shimizu, M.; Ishikawa, J.; Yano, Y.; Hoshide, S.; Shimada, K.; Kario, K. The relationship between the morning blood pressure surge and low-grade inflammation on silent cerebral infarct and clinical stroke events. Atherosclerosis 2011, 219(1), 316-21.
57. Ishikawa, J.; Tamura, Y.; Hoshide, S.; Eguchi, K.; Ishikawa, S.; Shimada, K.; Kario, K. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke 2007, 38(3), 911-7.
58. Weng, C.-M.; Chou, C.-H.; Huang, Y.-Y.; Lin, C.-C; Liu, Y.-W.; Tsai, W.-C. Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients. Heart Vessels 2010, 25(5), 386-91.
59. Ozdogan, M.; Bozcuk, H.; Coban, E. Low-grade inflammation in white-coat hypertension. Med. Sci. Monit. 2007, 13(12), CR570-3.
60. Hirano, T. Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem. Biophys. Res. Commun. 1999, 260(2), 303-8.
61. Sprague, A. H.; Khalil, R. A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 2009, 78(6), 539-52.
62. Ozaki, K.; Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 2002, 277(33), 29355-8.
63. Dinarello, C. A. Proinflammatory cytokines. Chest 2000, 118(2), 503-8.
64. Leibowitz, A.; Schiffrin, E. L. Immune mechanisms in hypertension. Curr. Hypertens. Rep. 2011, 13(6), 465-72.
65. Bautista, L. E.; Vera, L. M.; Arenas, I. A.; Gamarra, G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens. 2005, 19(2), 149-54.
66. Mauno, V.; Hannu, K.; Esko, K. Proinflammation and hypertension: a population-based study. Mediators Inflamm. 2008, 2008, 619704.
67. Morillas, P.; De Andrade, H.; Castillo, J.; Quiles, J.; Bertomeu-González, V.; Cordero, A.; Tarazón, E.; Roselló, E.; Portolés, M.; Rivera, M.; Bertomeu-Martínez, V. Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Rev. Esp. Cardiol. (Engl. Ed.) 2012, 65(9), 819-25.
68. Naya, M.; Tsukamoto, T.; Morita, K.; Katoh, C; Furumoto, T.; Fujii, S.; Tamaki, N.; Tsutsui, H. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens. Res. 2007, 30(6), 541-8.
69. Yu, X.; Yang, Z.; Yu, M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren. Fail. 2010, 32(4), 475-9.
70. Larrousse, M.; Bragulat, E.; Segarra, M.; Sierra, C; Coca, A.; De La Sierra, A. Increased levels of atherosclerosis markers in saltsensitive hypertension. Am. J. Hypertens. 2006, 19(1), 87-93.
71. Ohmori, R.; Momiyama, Y.; Taniguchi, H.; Takahashi, R.; Kusuhara, M.; Nakamura, H.; Ohsuzu, F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170(2), 333-7.
72. Minoretti, P.; Falcone, C; Calcagnino, M.; Emanuele, E.; Buzzi, M. P.; Coen, E.; Geroldi, D. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur. Heart J. 2006, 27(7), 802-7.
73. Irita, J.; Okura, T.; Manabe, S.; Kurata, M.; Miyoshi, K.-I.; Watanabe, S.; Fukuoka, T.; Higaki, J. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am. J. Hypertens. 2006, 19(3), 293-7.
74. Stepieh, E.; Wypasek, E.; Stopyra, K.; Konieczyhska, M.; Przybylo, M.; Pasowicz, M. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin. Biochem. 2011, 44(10-11), 826-31.
75. Golias, C; Tsoutsi, E.; Matziridis, A.; Makridis, P.; Batistatou, A.; Charalabopoulos, K. Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo 2007, 21(5), 757-69.
76. Chi, Z.; Melendez, A. J. Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis. Cell Adh. Migr. 2007, 1(4), 171-5.
77. Farzadnia, M.; Ayatollahi, H.; Hasan-Zade, M.; Rahimi, H. R. A comparative study of serum level of vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (ICAM-1) and high sensitive C - reactive protein (hs-CRP) in normal and preeclamptic pregnancies. Iran J. Basic Med. Sci. 2013, 16(5), 689-93.
78. Buemi, M.; Allegra, A.; Aloisi, C; Corica, F.; Alonci, A.; Ruello, A.; Montalto, G.; Frisina, N. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension 1997, 30(4), 845-7.
79. Palomo, I.; Marín, P.; Alarcón, M.; Gubelin, G.; Viñambre, X.; Mora, E.; Icaza, G. Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers. Clin. Exp. Hypertens. 2003, 25(8), 517-23.
80. Parissis, J. T.; Korovesis, S.; Giazitzoglou, E.; Kalivas, P.; Katritsis, D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int. J. Cardiol. 2002, 83(1), 13-21.
81. Glowinska, B.; Urban, M.; Peczynska, J.; Florys, B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005, 54(8), 1020-6.
82. Cottone, S.; Mulè, G.; Nardi, E.; Vadalà, A.; Lorito, M. C; Guarneri, M.; Arsena, R.; Palermo, A.; Cerasola, G. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J. Hypertens. 2007, 25(2), 423-8.
83. Vasilev, V.; Matrozova, J.; Elenkova, A.; Vandeva, S.; Kirilov, G.; Zacharieva, S. Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1 (sVCAM-1) as Circulating markers for endothelial dysfunction in patients with pheochromocytoma. Exp. Clin. Endocrinol. Diabetes 2013, 121(9), 551-5.
84. De Souza, C. A.; Dengel, D. R.; Macko, R. F.; Cox, K.; Seals, D. R. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am. J. Hypertens. 1997, 10(12 Pt 1), 1335-41.
85. Parissis, J. T.; Venetsanou, K. F.; Mentzikof, D. G.; Kalantzi, M. V.; Georgopoulou, M. V.; Chrisopoulos, N.; Karas, S. M. Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1. Eur. J. Intern. Med. 2001, 12(4), 350-356.
86. Chao, J.-T.; Davis, M. J. The roles of integrins in mediating the effects of mechanical force and growth factors on blood vessels in hypertension. Curr. Hypertens. Rep. 2011, 13(6), 421-9.
87. Xu, H.; Oliveira-Sales, E. B.; McBride, F.; Liu, B.; Hewinson, J.; Toward, M.; Hendy, E. B.; Graham, D.; Dominiczak, A. F.; Giannotta, M.; Waki, H.; Ascione, R.; Paton, J. F. R.; Kasparov, S. Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension. Cardiovasc. Res. 2012, 96(3), 552-60.
88. Cottone, S.; Mulè, G.; Nardi, E.; Lorito, M. C.; Guarneri, M.; Arsena, R.; Briolotta, C.; Vadalà, A.; Cerasola, G. Microalbuminuria and early endothelial activation in essential hypertension. J. Hum. Hypertens. 2007, 21(2), 167-72.
89. Ferroni, P.; Guadagni, F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc. Hematol. Disord. Drug Targets 2008, 8(3), 194-202.
90. Derosa, G.; D'Angelo, A.; Mugellini, A.; Pesce, R. M.; Fogari, E.; Maffioli, P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr. Med. Res. Opin. 2012, 28(9), 1435-45.
91. Yan, J.-C.; Ma, G.-S.; Wu, Z.-G.; Kong, X.-T.; Zong, R.-Q.; Zhan, L.-Z. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin. Chim. Acta 2005, 355(1-2), 191-6.
92. Alioglu, E.; Turk, U. O.; Bicak, F.; Tengiz, I.; Atila, D.; Barisik, V.; Ercan, E.; Akin, M. Vascular endothelial functions, carotid intima-media thickness, and soluble CD40 ligand levels in dipper and nondipper essential hypertensive patients. Clin. Res. Cardiol. 2008, 97(7), 457-62.
93. Rathcke, C. N.; Vestergaard, H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm. Res. 2006, 55(6), 221-7.
94. Diao, Y.-Y.; Lü, Q.-Z.; Yang, C.-S.; Wei, D. [Association between serum YKL-40 levels and endothelial function in hypertensive patients]. Zhonghua Xin Xue Guan Bing Za Zhi 2013, 41(2), 121-5.
95. Ma, W.-H.; Wang, X.-L.; Du, Y.-M.; Wang, Y.-B.; Zhang, Y.; Wei, D.-E.; Guo, L.-L.; Bu, P.-L. Association between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness in essential hypertension. BMC Cardiovasc. Disord. 2012, 12, 35.
96. Penders, J.; Delanghe, J. R. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin. Chim. Acta 2004, 346(2), 107-18.
97. Karthikeyan, V. J.; Lip, G. Y. H. Alpha 1-microglobulin: a further insight into inflammation in hypertension? Am. J. Hypertens. 2007, 20(9), 1022-3.
98. Vyssoulis, G. P.; Tousoulis, D.; Antoniades, C.; Dimitrakopoulos, S.; Zervoudaki, A.; Stefanadis, C. Alpha-1 microglobulin as a new inflammatory marker in newly diagnosed hypertensive patients. Am. J. Hypertens. 2007, 20(9), 1016-21.
99. Gunes, F.; Akbal, E.; Cakir, E.; Akyurek, O.; Altunbas, M.; Ozbek, M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern. Med. 2012, 51(6), 553-7.
100. Dogru, T.; Sonmez, A.; Tasci, I.; Yilmaz, M. I.; Erdem, G.; Erturk, H.; Bingol, N.; Kilic, S.; Ozgurtas, T. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J. Hum. Hypertens. 2007, 21, 173-5.
101. Laffer, C. L.; Bolterman, R. J.; Romero, J. C.; Elijovich, F. Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension 2006, 47(3), 434-40.
102. Rahman, S. T.; Lauten, W. B.; Khan, Q. A.; Navalkar, S.; Parthasarathy, S.; Khan, B. V. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am. J. Cardiol. 2002, 89(6), 686-90.
103. Eriksson, J. W.; Jansson, P.-A.; Carlberg, B.; Hägg, A.; Kurland, L.; Svensson, M. K.; Ahlström, H.; Ström, C.; Lönn, L.; Ojbrandt, K.; Johansson, L.; Lind, L. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008, 52(6), 1030-7.
104. Serg, M.; Kampus, P.; Kals, J.; Zagura, M.; Zilmer, M.; Zilmer, K.; Kullisaar, T.; Eha, J. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand. J. Clin. Lab. Invest. 2012, 72(5), 427-32.
105. Fici, F.; Celik, T.; Balta, S.; Iyisoy, A.; Unlu, M.; Demitkol, S.; Yaman, H.; Brambilla, G.; Kardesoglu, E.; Kilic, S.; Yokusoglu, M.; Grassi, G. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension. J. Cardiovasc. Pharmacol. 2013, 62(4), 388-93.
106. Ceron, C. S.; Rizzi, E.; Guimarães, D. A.; Martins-Oliveira, A.; Gerlach, R. F.; Tanus-Santos, J. E. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-P and MMPs, and decreases vascular remodeling in renovascular hypertension. Free Radic. Biol. Med. 2013, 65C, 47-56.
107. Celik, T.; Iyisoy, A.; Kursaklioglu, H.; Kardesoglu, E.; Kilic, S.; Turhan, H.; Yilmaz, M. I.; Ozcan, O.; Yaman, H.; Isik, E.; Fici, F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 2006, 24(3), 591-6.
108. Ma, R.; Yu, J.; Xu, D.; Yang, L.; Lin, X.; Zhao, F.; Bai, F. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J. Hypertens. 2012, 30(1), 210-6.
109. Fiordaliso, F.; De Angelis, N.; Bai, A.; Cuccovillo, I.; Salio, M.; Serra, D. M.; Bianchi, R.; Razzetti, R.; Latini, R.; Masson, S. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. Life Sci. 2007, 81(12), 951-9.
110. Unlu, M.; Karaman, M.; Ay, S. A.; Balta, S.; Cakar, M.; Demirkol, S.; Celik, T.; Arslan, E.; Demirbas, S.; Turker, T.; Yaman, H.; Bulucu, F.; Saglam, K. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin. Exp. Hypertens. 2013, 35(6), 418-23.
111. Derosa, G.; Cicero, A. F. G.; Carbone, A.; Querci, F.; Fogari, E.; D'Angelo, A.; Maffioli, P. Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients. Inflammation 2014, 37(1), 154-62.
112. Farah, R.; Khamisy-Farah, R.; Shurtz-Swirski, R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int. Angiol. 2013, 32(1), 85-93.
113. Martinez-Martin, F. J.; Rodriguez-Rosas, H.; Peiro-Martinez, I.; Soriano-Perera, P.; Pedrianes-Martin, P.; Comi-Diaz, C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J. Hum. Hypertens. 2011, 25(6), 346-53.
114. Farah, R.; Shurtz-Swirski, R. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients. Minerva Cardioangiol. 2008, 56(5), 467-76.
115. Nakamura, T.; Kawachi, K.; Saito, Y.; Saito, T.; Morishita, K.; Hoshino, J.; Hosoi, T.; Iwasaki, T.; Ohyama, Y.; Kurabayashi, M. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int. Heart. J. 2009, 50(4), 501-12.
116. Brili, S.; Tousoulis, D.; Antoniades, C; Vasiliadou, C; Karali, M.; Papageorgiou, N.; Ioakeimidis, N.; Marinou, K.; Stefanadi, E.; Stefanadis, C. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J. Am. Coll. Cardiol. 2008, 51(7), 742-9.
117. Hlubocká, Z.; Umnerová, V.; Heller, S.; Peleska, J.; Jindra, A.; Jáchymová, M.; Kvasnicka, J.; Horky, K.; Aschermann, M. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J. Hum. Hypertens. 2002, 16(8), 557-62.
118. Sakurabayashi-Kitade, S.; Aoka, Y.; Nagashima, H.; Kasanuki, H.; Hagiwara, N.; Kawana, M. Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 2009, 206(1), 54-60.
119. Rocha, R.; Martin-Berger, C. L.; Yang, P.; Scherrer, R.; Delyani, J.; McMahon, E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143(12), 4828-36.
120. Joffe, H. V.; Adler, G. K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail. Rev. 2005, 10(1), 31-7.
121. Irita, J.; Okura, T.; Jotoku, M.; Nagao, T.; Enomoto, D.; Kurata, M.; Desilva, V. R.; Miyoshi, K.-I.; Matsui, Y.; Uede, T.; Denhardt, D. T.; Rittiling, S. R.; Higaki, J. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am. J. Physiol. Renal. Physiol. 2011, 301(4), F833-44.
122. Marketou, M. E.; Kontaraki, J. E.; Tsakountakis, N. A.; Zacharis, E. A.; Kochiadakis, G. E.; Arfanakis, D. A.; Parthenakis, F.; Chlouverakis, G.; Vardas, P. E. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am. J. Cardiol. 2011, 107(1), 59-63.
123. Han, S. H.; Koh, K. K.; Quon, M. J.; Lee, Y.; Shin, E. K. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007, 190(1), 205-11.
124. Fliser, D.; Buchholz, K.; Haller, H.; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators, Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110(9), 1103-7.
125. Kurata, M.; Okura, T.; Irita, J.; Enomoto, D.; Nagao, T.; Jotoku, M.; Miyoshi, K.; Desilva, V. R.; Higaki, J. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J. Hum. Hypertens. 2011, 25(5), 334-9.
126. Gómez-García, A.; Martínez Torres, G.; Ortega-Pierres, L. E.; Rodríguez-Ayala, E.; Alvarez-Aguilar, C. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. Rev. Esp. Cardiol. 2007, 60(12), 1242-9.
127. Schneider, M. P.; Schmidt, B. M.; John, S.; Schmieder, R. E. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J. Hypertens. 2011, 29(9), 1757-64.
128. Leibovitz, E.; Schiffrin, E. L. PPAR activation: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 2007, 50(2), 120-5.
129. Dormandy, J. A.; Charbonnel, B.; Eckland, D. J. A.; Erdmann, E.; Massi-Benedetti, M.; Moules, I. K.; Skene, A. M.; Tan, M. H.; Lefèbvre, P. J.; Murray, G. D.; Standl, E.; Wilcox, R. G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R. J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J.; PROactive investigators, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005, 366(9493), 1279-89.
130. Koh, K. K.; Quon, M. J.; Han, S. H.; Chung, W.-J.; Ahn, J. Y.; Kim, J.-A.; Lee, Y.; Shin, E. K. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006, 29(2), 195-201.
131. Takase, H.; Nakazawa, A.; Yamashita, S.; Toriyama, T.; Sato, K.; Ueda, R.; Dohi, Y. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 2007, 56(4), 559-64.
132. De Ciuceis, C; Amiri, F.; Iglarz, M.; Cohn, J. S.; Touyz, R. M.; Schiffrin, E. L. Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br. J. Pharmacol. 2007, 151(1), 45-53.
133. Bae, E. H.; Kim, I. J.; Ma, S. K.; Kim, S. W. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertens. Res. 2010, 33(3), 255-62.
134. Choi, B. S.; Yang, H. J.; Ahn, K. O.; Lim, S. W.; Kim, S. H.; Kim, J. Y.; Li, C; Kim, Y. S.; Kim, J.; Bang, B. K.; Yang, C. W. Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats. Kidney Blood Press. Res. 2007, 30(4), 212-23.
135. Sugawara, A.; Uruno, A.; Kudo, M.; Matsuda, K.; Yang, C. W.; Ito, S. PPARγ agonist beyond glucose lowering effect. Korean J. Intern. Med. 2011, 26(1), 19-24.
136. Imig, J. D.; Walsh, K. A.; Hye Khan, M. A.; Nagasawa, T.; Cherian-Shaw, M.; Shaw, S. M.; Hammock, B. D. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor y agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp. Biol. Med. (Maywood) 2012, 237(12), 1402-12.